Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Aptevo Therapeutics stock last closed at $4.39, down 8.16% from the previous day, and has decreased 99.24% in one year. It has underperformed other stocks in the Biotechnology industry by 0.23 percentage points. Aptevo Therapeutics stock is currently +2.09% from its 52-week low of $4.30, and -99.13% from its 52-week high of $503.20.
At the moment, there are 405,464 APVO shares outstanding. The market capitalization of APVO is $1.78M. In the last 24 hours, 148,000 APVO shares were traded.
How to Buy Aptevo Therapeutics Stock
Not sure how to invest in Aptevo Therapeutics stock? Here's how.
Decide where to buy Aptevo Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you decide where to buy Aptevo Therapeutics stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Deposit funds into your investment account: Pick your method of payment and add your information.
Evaluate Aptevo Therapeutics stock: The Aptevo Therapeutics ticker symbol is APVO. Is Aptevo Therapeutics stock a good investment? Should you buy shares of APVO? How do APVO's underlying business fundamentals look? Do top analysts think Aptevo Therapeutics is a good buy? Why has APVO's stock price moved recently? (Hint: Our stock market research website can help you figure out if APVO is a good stock to buy).
Execute your APVO purchase: Decide if you will purchase APVO shares at the current market price or use a limit order to buy APVO shares at a specific price.
Keep an eye on your APVO investment: Create a watchlist to track your investment in Aptevo Therapeutics stock.
Step 1: Decide where to buy Aptevo Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy APVO shares.
A brokerage account is an investment account that allows you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to global markets: From Tech to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal info so you can buy APVO today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Aptevo Therapeutics stock
Once you have decided on the best place to buy Aptevo Therapeutics stock, it's important to evaluate their stock prior to investing, so you actually comprehend the risk and upside.
Aptevo Therapeutics Numbers
APVO Price
$4.39
1w %
-11.31%
1y %
-99.24%
5y %
-100%
P/E
0.02x
P/B
-1.21x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$23.70M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$1.78M
Next Earnings
N/A
Next Dividend
N/A
Aptevo Therapeutics Fundamentals
WallStreetZen was created to help everyday investors do more accurate fundamental analysis in minutes instead of hours.
Last year, APVO earnings were -$23.70M. During the past 2 year, APVO's earnings have increased by -95.05% per year. This was slower than the Biotechnology industry average of 8.66%.
Last year, APVO revenue was $0.00. During the past four year, APVO's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 43.24%.
No, Aptevo Therapeutics doesn't provide an income stream by paying out dividends.
APVO Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your APVO purchase
You have two main order types:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are mostly sufficient.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Press the Open button and eToro will place the order.
If you require more info about buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Aptevo Therapeutics share?
As of Jun 13, 2025, it costs $4.39 to buy one share of Aptevo Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $2, you can buy 0.456 shares of APVO.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.